The macroscopic, microscopic and spectrometric effects of various chemotherapeutic agents on the plasma-sprayed hydroxyapatite-coated implant surface.
The purpose of this research was to determine the nature of the residual hydroxyapatite (HA)-coated implant surface after treatment with various chemotherapeutic modalities, including: citric acid, chlorhexidine gluconate, hydrogen peroxide, tetracycline HCl, stannous fluoride, polymyxin B and a prototype plastic Cavitron tip. Implant surfaces were evaluated macroscopically, microscopically (scanning electron microscopy (SEM)) and spectrometrically (energy-dispersive spectrometry and X-ray diffraction). HA-substrate bond strength and dissolution testing was also performed for surfaces treated with a supersaturated citric acid solution. All treatments left either microscopic residues or a loss of surface roughness when viewed on SEM. A 30- to 60-s application of citric acid left a significantly greater coating thickness than all other treatments, whereas a 3-min application of citric acid removed significantly more HA than untreated controls. Significant changes in Ca/P ratios were seen with most treatments. The clinical significance of this phenomenon is not known. No treatments altered the crystallinity of the residual HA coating. A 1-min application of citric acid did not significantly alter the tensile bond strength of the coating to the substrate. The clinical significance of these findings is not known at present. However, when taken with results from previous studies, it appears that in treating the infected HA-coated implant surface, a 30- to 60-s application of citric acid (pH 1) may be beneficial in detoxifying the HA coating prior to regenerative procedures. Further in vitro and in vivo studies are necessary to evaluate the biological response to citric acid when used to detoxify the infected implant surface.
Zablotsky
M
M
Division of Peridontology, University of California San Francisco, CA 95821.
Meffert
R
R
Mills
O
O
Burgess
A
A
Lancaster
D
D
D000704:Analysis of Variance; D000891:Anti-Infective Agents, Local / Q000494:pharmacology*; D002710:Chlorhexidine / Q000737:chemistry / Q000494:pharmacology; D002951:Citrates / Q000737:chemistry / Q000494:pharmacology; D019343:Citric Acid; D015921:Dental Implants; D006801:Humans; D006861:Hydrogen Peroxide / Q000737:chemistry / Q000494:pharmacology; D006882:Hydroxyapatites / Q000737:chemistry*; D008855:Microscopy, Electron, Scanning; D011112:Polymyxin B / Q000737:chemistry / Q000494:pharmacology; D016459:Prosthesis-Related Infections / Q000188:drug therapy; D013053:Spectrophotometry; D013499:Surface Properties; D013752:Tetracycline / Q000737:chemistry / Q000494:pharmacology; D014002:Tin Fluorides / Q000737:chemistry / Q000494:pharmacology; D014464:Ultrasonic Therapy; D014961:X-Ray Diffraction
D000891:Anti-Infective Agents, Local; D002951:Citrates; D015921:Dental Implants; D006882:Hydroxyapatites; D014002:Tin Fluorides; D019343:Citric Acid; D006861:Hydrogen Peroxide; D013752:Tetracycline; D011112:Polymyxin B; D002710:Chlorhexidine